395 MG Pembrolizumab And Berahyaluronidase Alfa Injection

Get a Price/Quote

MOQ : 100 Packs

395 MG Pembrolizumab And Berahyaluronidase Alfa Injection Specification

Indication
Treatment of certain cancers including melanoma, non-small cell lung cancer, and others as determined by a healthcare professional

Dosage Form
Injection

Salt Composition
Pembrolizumab 395 mg and Berahyaluronidase alfa

Enzyme Types
Hyaluronidase (recombinant human) as Berahyaluronidase alfa

Feature
Prefilled syringe, ready-to-use, enhances monoclonal antibody absorption

Ingredients
Pembrolizumab, Berahyaluronidase alfa, excipients, sterile water for injection

Application
Intravenous administration

Ph Level
6.0 - 7.0

Temperature Needed For Fermentation
37C for recombinant production

Physical Color/Texture
Clear to slightly opalescent, colorless to pale yellow solution

Fermentation Smell
Odorless

Enzymatic Activity
Active hyaluronidase for improved tissue permeability

Storage Instructions
Store refrigerated at 2-8C, do not freeze, protect from light

Shelf Life
18 months

Contraindications
Known hypersensitivity to pembrolizumab, hyaluronidase, or any ingredient in the formulation

Compatibility
Compatible with standard IV infusion sets

Route of Administration
Intravenous (IV) use only

Prescription Status
Prescription only medicine

Sterility
Sterile preparation

Usage Precautions
To be administered under supervision of a qualified oncologist

Molecular Weight
Pembrolizumab: ~149 kDa, Berahyaluronidase alfa: ~61 kDa

Container Material
Glass vial with rubber stopper and aluminium seal

Pack Size
Single-dose vial

395 MG Pembrolizumab And Berahyaluronidase Alfa Injection Trade Information

Minimum Order Quantity
100 Packs

Payment Terms
Cash in Advance (CID)

Supply Ability
5000 Packs Per Month

Delivery Time
10 Days

Main Domestic Market
All India

About 395 MG Pembrolizumab And Berahyaluronidase Alfa Injection

Capitalise on the in-demand 395 MG Pembrolizumab and Berahyaluronidase Alfa Injection, a paragon of precision for intravenous cancer therapy. With its wondrous combination of Pembrolizumab (395 mg) and Berahyaluronidase alfa, this single-dose, ready-to-use sterile vial promises optimum efficacy and enhanced monoclonal antibody absorption. Last chance to secure this prescription-only solution, expertly housed in a glass vial, compatible with standard IV sets. Ideal for a wide spectrum of oncology indications, it exemplifies reliability and innovation-perfect for traders, suppliers, and exporters seeking quality in cancer care.

Special Features and Clinical Applications

This injection boasts optimum efficacy owing to its unique combination of Pembrolizumab and recombinant human Berahyaluronidase alfa. Designed for intravenous administration, it features a prefilled, ready-to-use syringe that ensures quick preparation and reduces dosage errors. The active hyaluronidase enzyme uniquely enhances tissue permeability, allowing improved absorption of the monoclonal antibody. Suitable for hospital and clinic settings, the application surface targets systemic cancer therapy, effectively addressing conditions like melanoma and non-small cell lung cancer under oncologist supervision.

Export Markets, Samples & Policy Overview

395 MG Pembrolizumab and Berahyaluronidase Alfa Injection is sought after in global markets, with India as a trusted exporter, supplier, and trader. The list price varies by exchange terms, and estimates are provided upon inquiry to ensure competitive deals. Samples can be made available for evaluation, particularly for institutional buyers, following an established sample policy that outlines eligibility, shipping, and testing protocols. Leverage this product's international demand to support your oncology supply requirements efficiently.

FAQ's of 395 MG Pembrolizumab And Berahyaluronidase Alfa Injection:

Q: How should the 395 MG Pembrolizumab And Berahyaluronidase Alfa Injection be administered?

A: This injection is intended for intravenous (IV) use only and must be administered under the supervision of a qualified oncologist in a clinical setting, using compatible standard IV infusion sets.

Q: What are the main clinical indications for this injection?

A: The injection is indicated for the treatment of various cancers, including melanoma, non-small cell lung cancer, and other malignancies as advised by a healthcare professional.

Q: When should this injection be avoided?

A: It should not be used in patients with known hypersensitivity to pembrolizumab, hyaluronidase, or any of the formulation ingredients. Always consult the prescribing information and your oncologist before administration.

Q: What are the benefits of adding Berahyaluronidase Alfa to Pembrolizumab?

A: Berahyaluronidase alfa improves tissue permeability, allowing for better and more efficient absorption of pembrolizumab, potentially enhancing the therapeutic outcome in cancer treatment.

Q: Where should the product be stored and how long is its shelf life?

A: Store the injection refrigerated at 2-8C, protected from light and never frozen. The shelf life is 18 months from the date of manufacture.

Q: What is the process to obtain a sample for institutional or export use?

A: Interested buyers can request a sample by contacting the exporter. Samples are subject to eligibility, adherence to sample policy, and may involve estimates for list price and shipping, ensuring compliance with local regulations.

Tell us about your requirement